SEOUL-VIOSYS
Seoul Viosys (“SVC”) (KOSDAQ: 092190), a subsidiary of Seoul Semiconductor Co., Ltd., has won a patent litigation against a European home appliance distributor that infringed its Violeds technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005048/en/
In February 2022, Seoul Viosys filed patent litigation against FTHMM International B.V., a Netherlands trading company, in The Hague District Court of the Netherlands, seeking a preliminary injunction against the sales of infringing UV LED products. The asserted patent relates to Violeds technology that can effectively disinfect water, air space, and surfaces by using ultraviolet lights.
According to the cease and desist declaration approved by the court, FTHMM acknowledged infringing Seoul Viosys’ patent and will be required to cease all sales of infringing UV LED products and destroy any such products. FTHMM must also pay 500 Euro per product for any instances of non-compliance.
This litigation arose out of an earlier patent lawsuit filed by Seoul Viosys against Fnac Darty Group, a large European retailer, in France. In September 2021, the Judicial Court of Paris ordered the search and seizure of evidence of suspected infringement. Based on that seizure, Seoul Viosys learned that accused UV LED products are being imported and distributed from the Netherlands.
Since early 2000, Seoul Viosys has co-developed and mass-produced the world's first UV LED that emits UV light with optical semiconductor technology, as well as cutting edge sterilization and purification technology utilized in home appliances with more than 5,000 patent portfolios.
“As the UV LED market grows, distribution of copycat products has increased significantly,” said Young-joo Lee, Seoul Viosys CEO. “Seoul Viosys’ patented technology is essential for manufacturing UV LEDs, and Seoul Viosys will continue to enforce and protect its hard-earned patented technology around the world.”
Seoul Viosys, SETi, and their strategic partners are actively enforcing patent rights against infringers around the world. They already obtained a series of permanent injunctions judgments for patent infringement in the U.S. and Europe against UV LED products from various LED manufacturers, such as RayVio, Everlight, Bolb, Epileds, LED Engin, and SL Vionics (previous name “Semicon Light”). They continue to pursue additional enforcements against some of those manufacturers.
About Seoul Viosys
Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2019). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005048/en/
Link:
Social Media:
https://www.facebook.com/violedsTechnologykorea/?brand_redir=1698430287094913
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Brings Together Sport Stars and Legends, Leaders and Decision-Makers on the Largest Global Platform to Shape the Future of Sports: the World Sports Summit18.12.2025 14:40:00 CET | Press release
Under the directives of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum and the supervision of the Dubai Sports Council- The Summit, under the theme ‘Uniting the World Through Sports’, aligns with the objectives of Dubai Sports Sector Strategic Plan 2033- A comprehensive programme will address the future of sports, development of the sector and more The Dubai Sports Council has announced the launch of the World Sports Summit (WSS), which will take place under the directives of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, Minister of Defence and Chairman of the Executive Council of Dubai. The event is set to be held from December 29-30, 2025 at Madinat Jumeirah in Dubai, under the theme ‘Uniting the World Through Sports’. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218607571/en/ Dubai Brings Together Sport Stars and Legends, Leaders and Decisi
Regula Wins High Customer Marks and Strong Momentum in G2’s Winter 2026 Grid Reports for Identity Verification18.12.2025 14:11:00 CET | Press release
Regula, a global developer of identity verification solutions, has been recognized by customers on G2’s review platform as one of the fastest-rising and most trusted vendors in the identity verification market. Regula is named as a Leader in three G2 Winter 2026 Grid® Reports for Identity Verification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218134153/en/ Regula is recognized as a Leader in G2’s Winter 2026 Grid Reports for Identity Verification, reflecting strong customer satisfaction and enterprise-grade IDV capabilities. This season, Regula earned a Leader placement in G2’s Overall Grid® for Identity Verification Software, reflecting strong customer satisfaction and a growing presence in the market. The company was also named a Leader in the Momentum Grid® Report for Identity Verification, highlighting accelerating demand for Regula’s solutions and increasingly positive feedback from users. In addition, Regula a
Aptiv and Vecna Robotics to Develop Next Generation Autonomous Mobile Robots18.12.2025 14:00:00 CET | Press release
Collaboration to Deliver Safer, Smarter, and Cost-Effective Automation for Warehouses and Factories Aptiv PLC (NYSE: APTV), a global industrial technology leader, and Vecna Robotics, a pioneer in AI-driven autonomous material handling solutions, today announced a strategic collaboration to co-develop next-generation Autonomous Mobile Robot (AMR) solutions designed to deliver cost-efficient automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218958100/en/ Aptiv’s advanced perception portfolio and machine learning technologies will be integrated into Vecna Robotics’ platform. This partnership combines Aptiv’s industry-leading portfolio, with Vecna Robotics’ advanced autonomy and orchestration platform to provide safer, more efficient, and scalable material handling systems. “Automation is transforming the way goods move through warehouses and factories, with devices that sense, think and act in real time,” said Javed
Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions18.12.2025 14:00:00 CET | Press release
Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biologyLead program ST-905, a potent M1/M4 muscarinic agonist, currently in Phase 1 clinical developmentSecond program ST-901, a novel NMDA antagonist, currently in IND-enabling studies and expected to enter Phase 1 development next yearSeries A co-led by Dexcel Pharma and Third Rock Ventures with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept. Schizophrenia and other psychotic disorder
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
